menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Poster Pearl: Imaging-Based Localization for MCED Tests Yields Lower Diagnostic Burden

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    Blood-based multi-cancer early detection (MCED) tests are currently being developed to increase the number of cancers that can be detected in adults, but it requires the localization of the tissue of origin (TOO) in patients with cancer-suspected results using either molecular- or imaging-based strategies. To better understand the diagnostic burden associated with these MCED TOO localization strategies, a poster presented at the 2023 American Association for Cancer Research Annual Meeting evaluated published research and found that imaging-based localization had a lower diagnostic burden. Dive further into the results with Dr. Betsy O’Donnell, co-author of the poster and Director of Early Detection and Prevention of Malignant Conditions at the Dana-Farber Cancer Institute.

    This is a non-certified educational series produced and controlled by ReachMD. This series is intended for healthcare professionals only. This program discusses a technology under development. Any features discussed describe current development goals. It has not been cleared or approved by the U.S. FDA or any other national regulatory authority.

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Sponsored by

  • Overview

    Blood-based multi-cancer early detection (MCED) tests are currently being developed to increase the number of cancers that can be detected in adults, but it requires the localization of the tissue of origin (TOO) in patients with cancer-suspected results using either molecular- or imaging-based strategies. To better understand the diagnostic burden associated with these MCED TOO localization strategies, a poster presented at the 2023 American Association for Cancer Research Annual Meeting evaluated published research and found that imaging-based localization had a lower diagnostic burden. Dive further into the results with Dr. Betsy O’Donnell, co-author of the poster and Director of Early Detection and Prevention of Malignant Conditions at the Dana-Farber Cancer Institute.

    This is a non-certified educational series produced and controlled by ReachMD. This series is intended for healthcare professionals only. This program discusses a technology under development. Any features discussed describe current development goals. It has not been cleared or approved by the U.S. FDA or any other national regulatory authority.

Facebook Comments

Schedule14 Apr 2024